Literature DB >> 15933983

A randomized prospective study of valvulotome efficacy in in situ reconstructions.

J Malmstedt1, R Takolander, E Wahlberg.   

Abstract

OBJECTIVES: To compare the efficacy of valvulotomes during in situ bypass surgery.
DESIGN: A randomized prospective blinded study.
MATERIALS AND METHODS: Thirty PAD patients scheduled for infrainguinal greater saphenous vein bypass were randomized to use of adjustable or fixed valvulotomes for valve destruction. Valvulotomy was performed after construction of the proximal anastomosis. The efficacy of valve destruction was determined by angioscopy after completion of the distal anastomosis by a separate blinded examiner.
RESULTS: A total of 123 valves were evaluated, 61 after use of an adjustable and 62 with a fixed valvulotome. There was no difference ( p = .88) in number of retained valves between the two groups ( n = 16, 17, respectively). The majority of incompletely destroyed valves were found in the proximal parts of the graft (46%, 13 out of 28). The primary patency at 30 days was 100 and 79%, respectively, p = .09).
CONCLUSIONS: No significant difference in efficacy between valvulotomes was found. Both types tend to miss a large proportion of proximal valves.

Entities:  

Mesh:

Year:  2005        PMID: 15933983     DOI: 10.1016/j.ejvs.2005.02.052

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  2 in total

1.  The results of in situ saphenous vein bypass for infrainguinal arterial reconstruction: Comparison between two types of valvulotomes.

Authors:  Yuichi Izumi; Katsuaki Magishi; Noriyuki Shimizu
Journal:  Int J Angiol       Date:  2010

2.  A swine model of reproducible timed induction of peripheral arterial shunt failure: Developing warning signs of imminent shunt failure.

Authors:  David P Stonko; Neerav Patel; Joseph Edwards; Hossam Abdou; Eric Lang; Noha N Elansary; Rebecca Treffalls; Joseph White; Jonathan J Morrison
Journal:  JVS Vasc Sci       Date:  2022-08-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.